2,2-bis-(hydroxymethyl)cyclopropylidenemethyl-purines and -pyrimidines as antiviral agents
Abstract
Compounds which are active against viruses have the following formulas: wherein B is a purine or pyrimidine heterocyclic ring or base. In a preferred embodiment, the purine include 6-aminopurine (adenine), 6-hydroxypurine (hypoxanthine), 2-amino-6-hydroxypurine (guanine), 2,6-diamino-purine, 2-amino-6-azidopurine, 2-amino-6-halo substituted purines such as 2-amino-6-chloropurine, 2-amino-6-fluoropurine, 2-amino-6-alkoxypurines such as 2-amino-6-methoxypurine, 2-amino-6-cyclopropylaminopurine, 2-amino-6-alkylamino or 2-amino-6-dialkylamino substituted purines, 2-amino-6-thiopurine, 2-amino-6-alkylthio substituted purines, 3-deazapurines, 7-deazapurines and 8-azapurines. The pyrimidine incorporates cytosine, uracil and thymine, 5-halo substituted cytosines and uracils, 5-alkyl substituted cytosines and uracils including derivatives with a saturated or unsaturated alkyl group and 6-azapyrimidines.
Claims
exact text as granted — not AI-modified1. A compound having the formula:
wherein B is a 3-deazapurine, 7-deazapurine, 8-azapurine, or pyrimidine, and pharmaceutically acceptable salts and prodrugs thereof.
2. The compound of claim 1 , wherein B is selected from the group consisting of 3-deazapurines, 7-deazapurines, and 8-azapurines.
3. The compound of claim 1 , wherein the pyrimidine is selected from the group consisting of cytosine 5-halo substituted cytosines (wherein halo is fluoro, chloro, bromo, or iodo), thymines, uracils, 5-alkyl or alkenyl uracils, and 6-azapyrimidines.
4. The compound of claim 1 , wherein the compound is selected from the group consisting of (Z)-1-{[2,2-bis-(hydroxymethyl)cyclo-propylidene]methyl}cytosine(1e), (Z)-1-{[2,2-bis-(hydroxymethyl)cyclo-propylidene]methyl}thymine(1f), (E)-1-{[2,2-bis-(hydroxymethyl)cyclo-propylidene]methyl}cytosine(2e), and (E)-1-{[2,2-bis-(hydroxymethyl)cyclo-propylidene]methyl}thymine(2f).
5. A composition comprising a compound of any one of claims 1 - 4 and a pharmaceutically acceptable carrier.
6. A method of treating of a mammal infected with a virus selected from the group consisting of HHV, VZV, HCMV, EBV, HSV-1 and HSV-2, comprising a step of administering to said mammal a compound according to any one of claims 1 - 4 and combinations thereof.
7. The method of claim 6 , wherein said mammal is a human.
8. The method of claim 6 , further comprising a step of administering an additional compound.
9. The method of claim 8 , wherein said additional compound is selected from the group consisting of acyclovir, ganciclovir, zidovudine, AZT, ddl, ddc, 3TC, d4T, foscarnet, cidofovir, fomivirsen, and combinations thereof.Join the waitlist — get patent alerts
Track US8232275B2 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.